LUNG MEXC RealStocks
Own real LUNG shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 19:49:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pulmonx Corporation (LUNG) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2.86, with a market capitalization of $124.55M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.13 to $3.25. This page covers its latest market performance, valuation, price trends and company information.
$124.55M | |
$2.99 | |
$3.09 | |
$2.60 | |
$3.00 | |
681.70K | |
627.49K | |
-- | |
$3.25 | |
$1.13 | |
-- | |
-- |
Pulmonx Corporation (LUNG) last closed at $2.86 as of 2026-11-14 00:31:00, down 4.83% ($0.15) from the previous close of $3.00.
During the latest regular trading session, LUNG traded between $2.60 and $3.09, with a volume of 681.70K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Pulmonx Corporation (LUNG) moved from $2.56 to $2.86, representing a gain of 11.76% ($0.30).
The stock traded between $2.48 and $3.17 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 792.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81.7%
LUNG is currently trading at $2.86, placing it 81.7% of the way from its 52-week low of $1.13 to its 52-week high of $3.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 296 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pulmonx Corporation (LUNG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LUNG, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LUNG shares and USD.
LUNG Shares to USD
1.00 LUNG shares = 2.861 USD
Calculations are estimates based on the latest available price and are for reference only.